Health Canada Approves AbbVie's Rinvoq (Upadacitinib, 45 mg [Induction Dose] And 15 mg And 30 mg [Maintenance Dose]) For Moderately To Severely Active Ulcerative Colitis In Adult Patients Who Have Demonstrated Prior Treatment Failure
Portfolio Pulse from Benzinga Newsdesk
Health Canada has approved AbbVie's Rinvoq for moderately to severely active ulcerative colitis in adult patients who have demonstrated prior treatment failure. The approval is for the 45 mg induction dose and the 15 mg and 30 mg maintenance doses.
July 25, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The approval of Rinvoq by Health Canada could potentially increase AbbVie's market share in the ulcerative colitis treatment market, which may have a positive impact on the company's stock.
The approval of a new drug by a regulatory body often leads to increased sales and revenues for the company that produces the drug. In this case, AbbVie's Rinvoq has been approved by Health Canada for the treatment of ulcerative colitis in adults, which could lead to increased sales and revenues for AbbVie. This could potentially have a positive impact on AbbVie's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100